Published in Medical Imaging Week, March 4th, 2006
Surgeons in Switzerland conducted a study "to define the most sensitive biochemical test to establish the diagnosis of pheochromocytoma, and also to assess the potential role of iodine 131-labeled metaiodobenzylguanidine scintigraphy (I-MIBG) in the diagnosis of this tumor."
"Pheochromocytoma is a rare, catecholamine-producing tumor with preferential localization in the adrenal gland," explained U. Güller and colleagues at University Hospital Basel. "Despite its importance, the most sensitive test to establish the diagnosis remains to be defined."
Want to see the full article?
Welcome to NewsRx!
Learn more about a six-week, no-risk free trial of Medical Imaging Week
NewsRx also is available at LexisNexis, Gale, ProQuest, Factiva, Dialog, Thomson Reuters, NewsEdge, and Dow Jones.